Literature DB >> 29236629

The Fate of FDA Postapproval Studies.

Lisa M Schwartz1, Steven Woloshin1, Thomas J Moore2.   

Abstract

Mesh：

Year:  2017        PMID： 29236629     DOI： 10.1056/NEJMc1713794

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  1 in total

1.  Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016.

Authors:  Thomas J Moore; Hanzhe Zhang; Gerard Anderson; G Caleb Alexander
Journal:  JAMA Intern Med       Date:  2018-11-01       Impact factor: 21.873
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.